Click here to view online. Add this email to your safelist.

AstraZeneca logo

Update on CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19

12 November 2020

The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the trials.

Read more  Read more

RSS Feed  RSS Feed Twitter  Follow us on Twitter LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2020

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.